Therapetutic treatment for human T cell lymphotrophic virus type 1 infection
AssigneeEli Lilly and Company
InventorsMichael R. Jirousek, Douglas Kirk Ways, Lawrence E. Stramm
Life of this patent
Estimating the term…
Abstract
A method for treating human T cell lymphotrophic virus type 1 infection using an isozyme selective PKC inhibitor, particularly using the isozyme selective PKC inhibitor, (S)-3,4-N,N'-1,1'-((2"-ethoxy)-3'"(O)-4'"-(N,N-dimethylamino)-butane)-bis -(3,3'-indolyl)!-1(H)-pyrrole-2,5-dione hydrochloride salt.
Claims27
A method for inhibiting human T cell lymphotrophic virus type 1 replication in an infected cell which comprises contacting the cell with a viral replication inhibiting amount of an inhibitor of the .beta. isozyme of protein kinase C.
A method for inhibiting an effect of Tax 1 viral protein activity in a cell which comprises contacting the cell with an viral protein activity inhibiting amount of an inhibitor of the .beta. isozyme of protein kinase C.
A method for treating a mammal infected with human T cell lymphotrophic virus type 1, which comprises administering to the mammal a therapeutically effective amount of an inhibitor of the .beta. isozyme of protein kinase C.
A method for treating adult T cell leukemia associated with human T cell lymphotrophic virus type 1 infection, which comprises administering to an adult in need of such treatment a therapeutically effective amount of an inhibitor of the .beta. isozyme of protein kinase C.
A method for treating a chronic neurodegenerative disorder associated with human T cell lymphotrophic virus type 1 infection, which comprises administering to a mammal in need of such treatment a therapeutically effective amount of an inhibitor of the .beta. isozyme of protein kinase C.
Dependencies are inferred from the claim text.